Oral Soluble Film Products for Epilepsy: Clobazam (COSF) and Diazepam (DBSF)

Similar documents
Clinical Study Synopsis for Public Disclosure

Clinical Study Synopsis for Public Disclosure

PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI

Dr. M.Mothilal Assistant professor

Ph D. Synopsis 4. WORK PLAN AND METHODOLOGY

Clinical Trials A Practical Guide to Design, Analysis, and Reporting

Rescue medications. What are rescue medications? Ideal rescue medication. Why use rescue medications?

PUBLIC ASSESSMENT REPORT Scientific Discussion

Current Challenges and Opportunities in Demonstrating Bioequivalence

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment:

Pharmacokinetic and absolute bioavailability studies in early clinical development using microdose and microtracer approaches.

Pentoxifylline Extended-Release Tablets 400 mg

Clinical Study Synopsis for Public Disclosure

Public Assessment Report. Scientific discussion. Lorazepam GenRx 1 mg and 2.5 mg tablets. (lorazepam) NL/H/3485/ /DC

SCIENTIFIC DISCUSSION

Clinical Endpoint Bioequivalence Study Review in ANDA Submissions. Ying Fan, Ph.D.

SCIENTIFIC DISCUSSION. Antimycobacterial (J04AC01).

Effect of Common Excipients on the Oral Drug Absorption of Biopharmaceutics Classification System Class 3 Drugs

A Pharmacokinetic Study to Compare Two Simultaneous 400 µg Doses with a Single 800 µg Dose of Oral Transmucosal Fentanyl Citrate

Development of Canagliflozin: Mechanistic Absorption Modeling During Late-Stage Formulation and Process Optimization

Public Assessment Report Scientific discussion. Anastrozole Bluefish 1 mg film-coated tablets (anastrozole) SE/H/781/01/DC

Final Report (Amendment 1) April 11, 2006 Page 4 of 50

Study No: LOV OMA-104 Title : Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Statistical Methods

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

Clinical Study Synopsis for Public Disclosure

SCIENTIFIC DISCUSSION

BASIC PHARMACOKINETICS

Public Assessment Report Scientific discussion. Ivabradine Grindeks 5 mg and 7.5 mg and filmcoated. Ivabradine hydrochloride ES/H/0375/ /DC

Public Assessment Report. Scientific discussion. Metoprololsuccinat Actavis. Prolonged release tablets 25 mg, 50 mg, 100 mg and 200 mg

Japanese, Korean and Chinese subjects had also lived outside their respective countries for less than 10 years.

Brand and Generic Drugs. Educational Objectives. Absorption

SCIENTIFIC DISCUSSION

Absolute bioavailability and pharmacokinetic studies in early clinical development using microdose and microtracer approaches.

TCP Transl Clin Pharmacol

USING PBPK MODELING TO SIMULATE THE DISPOSITION OF CANAGLIFLOZIN

Public Assessment Report Scientific discussion. Ibuprofen Idifarma 4 mg/ml solution for infusion. Ibuprofeno ES/H/0256/001/DC

Product: Cinacalcet hydrochloride Clinical Study Report: Page 2 of 670

Public Assessment Report Scientific discussion. Ibuprofen 400 mg/100 ml solution for infusion & Ibuprofen 600 mg/100 ml solution for infusion

BIOPHARMACEUTICS and CLINICAL PHARMACY

Application of IVIVCs in Formulation Development Douglas F Smith

Define the terms biopharmaceutics and bioavailability.

BCS: Dissolution Testing as a Surrogate for BE Studies

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

Dosing Information. The First & Only FDA-approved Spironolactone Oral Suspension P HARM A. Exclusively from

Effect of Multiple-Dose Ketoconazole and the Effect of Multiple-Dose Rifampin on Pharmacokinetics (PK) of the HCV NS3 Protease Inhibitor Asunaprevir

Mylan Laboratories Limited F-4 & F-12, Malegaon MIDC, Sinnar Nashik Maharashtra State, India

SCIENTIFIC DISCUSSION

SCIENTIFIC DISCUSSION

Interested parties (organisations or individuals) that commented on the draft document as released for consultation.

SINGLE-DOSE AND STEADY-STATE PHARMACOKINETICS OF MOXDUO, A DUAL-OPIOID FORMULATION CONTAINING A FIXED RATIO OF MORPHINE AND OXYCODONE

FDB FOOD AND DRUGS BOARD G H A N A GUIDELINES FOR CONDUCTING BIOEQUIVALENCE STUDIES

Revised European Guideline on PK and Clinical Evaluation of Modified Release Dosage Forms

Bioequivalence of MR Products. AGAH Conference on the New European Modified Release Guideline Bonn, June 15 th, 2015

Public Assessment Report Scientific discussion. Flucloxacillin Orion (flucloxacillin sodium) SE/H/981/03/DC

SCIENTIFIC DISCUSSION. Lopinavir and Ritonavir 200 mg/50 mg Tablets * Name of the Finished Pharmaceutical Product:

NASDAQ: ZGNX. Company Presentation. October 2017

Public Assessment Report Scientific discussion. Ciprofloxacin Pfizer (Ciprofloxacin hydrochloride) SE/H/803/01-03/DC

Jieon Lee 1, AnHye Kim 1, Kyung-Sang Yu 1, Jae-Yong Chung 2, Sung-Vin Yim 3 and Bo-Hyung Kim 3 * 1 ORIGINAL ARTICLE

SCIENTIFIC DISCUSSION

Case Study 2 Answers Spring 2006

Public Assessment Report. Scientific discussion. Carvedilol Aurobindo 6.25 mg and 25 mg, film-coated tablets (carvedilol) NL/H/2609/ /MR

Public Assessment Report Scientific discussion. Levodopa/Carbidopa/Entacapone Mylan (levodopa, carbidopa, entacapone) SE/H/1548/01-06/DC

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

Biowaiver and Dissolution Profile Comparison

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

Public Assessment Report Scientific discussion. Methylphenidate E Consult (methylphenidate hydrochloride) Asp no: , ,

Use of Bridging Justifications to Support the Safety of Excipients in Generic Drug Products

Public Assessment Report Scientific discussion. Doxazosin NM Pharma 4 mg prolonged-release tablet (Doxazosin mesilate) SE/H/465/01

SCIENTIFIC DISCUSSION

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

Public Assessment Report. Scientific discussion. Ropinirol Actavis. Ropinirole hydrochloride DK/H/1212/ /DC

Received: ; Revised; Accepted: A REVIEW ON BIOAVAILABILITY AND BIOEQUIVALENCE STUDY Shashi Kant*, Bharat Parashar

Modeling and Simulation to Support Development and Approval of Complex Products

Completion of the development of a formulation: Requirements for compliance check vs. requirements for Marketing Authorisation

Decentralised Procedure. Public Assessment Report. Zolmitriptan Renantos 2.5 mg Orodispersible film 5 mg Orodispersible film DE/H/2295/ /DC

SCIENTIFIC DISCUSSION. Efavirenz

SCIENTIFIC DISCUSSION. AkuriT-3 Tablets*

Bioequivalence Study of Sildenafil 20 mg Tablets in Healthy Thai Male Volunteers

Abacavir (as sulfate) 300 mg tablets WHOPAR part 6 May 2016 (Hetero Labs Ltd), HA575

Prasugrel hydrochloride film-coated tablets 5 mg and 10 mg product-specific bioequivalence guidance

Public Assessment Report. Scientific discussion. Desloratadine Lek 5 mg film-coated tablets. (Desloratadine) DK/H/2041/001/DC.

Amoxicillin 40 mg Clavulanic acid 10 mg. Clavulanic acid 10 mg. Clavulanic acid 10 mg. Clavulanic acid 10 mg

London Medicines Information Service

Public Assessment Report. Scientific discussion. Rabeprazolnatrium Torrent Pharma. 10 mg and 20 mg gastro-resistant tablets. Rabeprazole sodium

Cantor Global Healthcare Conference

Public Assessment Report. Scientific discussion. Tevalukast Chewable tablets 4 mg and 5 mg. Montelukast sodium DK/H/1331/ /DC

Draft Agreed by Pharmacokinetics Working Party February Adoption by CHMP for release for consultation 1 April 2016

JBPOS0101: A New Generation mglur- and BBB- Targeted AED for the Treatment of Super-Refractory Status Epilepticus (SRSE)

EMA/EGA. Session 1: orally administered Modified Release Products European Regulatory Requirements London 30 April 2015 Dr.

CALCIUM AND GOOD HEALTH: Where nutritionally essential minerals are concerned, calcium is truly in a class by itself. The daily requirements for

SCIENTIFIC DISCUSSION

Year in review. Vit Perlik Director of Regulatory Science and Clinical Development

ESETT ELIGIBILITY OVERVIEW. James Chamberlain, MD

Pelagia Research Library

Biopharmaceutics of Non-Orally Administrated Drugs

Clinical Trial Results Summary Study EN

Photo (compulsory) Columbia University Medical Center, New York, NY 2. University of Southern California, Keck School of Medicine, Los Angeles, CA 3

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Lack of pharmacokinetic interaction between the oral anti-influenza neuraminidase inhibitor prodrug oseltamivir and antacids

SCIENTIFIC DISCUSSION. Darunavir

Transcription:

Oral Soluble Film Products for Epilepsy: Clobazam (COSF) and Diazepam (DBSF) Michael A. Rogawski, M.D., Ph.D. Professor of Neurology and Pharmacology School of Medicine University of California, Davis

Conflict of Interest Dr. Rogawski serves as a paid consultant for Aquestive Therapeutics. Dr. Rogawski is currently or has previously served as consultant to other companies developing technology for similar applications, including Upsher-Smith Laboratories and Epalex Corporation.

How Does PharmFilm Work? Polymers are used as film formers to hold API and excipients in place Patented techniques are used to ensure the API is uniformly distributed throughout the film ph modifiers and permeation enhancers cause transport across the buccal mucosa Begins to dissolve immediately on application to mucosa API released from buccal film is absorbed by the transmucosal route and is also swallowed 3

Clobazam Oral Soluble Film (COSF) An new alternative clobazam dosage form for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in patients aged 2 years and older (outside the United States for anxiety disorders and epilepsy) May be easier for some caregivers to administer than oral tablets or oral liquid suspension Demonstrates capability of film technology

Bioequivalence Study of COSF (162018) Open-label, randomized, single-dose, 4-period, 4-arm, crossover, comparative bioavailability study Healthy, nonsmoking male and female volunteers (N=51) Treatments COSF 10 mg (N=47) COSF 20 mg (N=45) Onfi (clobazam) Tablet 10 mg (N=47) Onfi (clobazam) Tablet 20 mg (N=47) Washout: 28 days between dosing Blood sampling time points: 0.333, 0.667, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 24, 28, 36, 48, 72, 96, 144, 240, 360, and 504 hours postdose in each period Safety: vital signs, physical exam, clinical labs, adverse events Data on file, Aquestive Therapeutics. 5

Mean Plasma Concentration Profiles: COSF vs Onfi (Study 162018) Clobazam 20 mg OSF Fasting Onfi 20 mg Tablet Fasting Clobazam 10 mg OSF Fasting Onfi 10 mg Tablet Fasting Data on file, Aquestive Therapeutics. 6

20 mg Bioequivalence (Study 162018) Bioequivalence of Clobazam Oral Soluble Film 20 mg vs Onfi Tablets 20 mg PK Population (N=45) Least-Squares Geometric Means Parameter COSF 20 mg Onfi 20 mg Ratio of Geo Means 1 (%) 90% Geometric CI 2 Lower Upper AUC 0-t (ng h/ml) 10531.45 10152.24 103.74 101.32 106.21 AUC 0-inf (ng h/ml) 10712.10 10344.68 103.55 101.16 106.00 C max (ng/ml) 386.59 376.84 102.59 95.43 110.28 1 Calculated using least-squares means according to formula e (Difference) X 100. 2 90% geometric confidence interval using ln-transformed data. Data on file, Aquestive Therapeutics. 7

10 mg Bioequivalence (Study 162018) Bioequivalence of Clobazam Oral Soluble Film 10 mg vs Onfi Tablets 10 mg PK Population (N=47) Least-Squares Geometric Means Parameter COSF 10 mg Onfi 10 mg Ratio of Geo Means 1 (%) 90% Geometric CI (%) 2 Lower Upper AUC 0-t (ng h/ml) 4554.83 4583.30 99.38 96.81 102.02 AUC 0-inf (ng h/ml) 4714.55 4759.87 99.05 96.72 101.43 C max (ng/ml) 179.96 188.53 95.45 90.19 101.03 1 Calculated using least-squares means according to formula e (Difference) X 100. 2 90% geometric confidence interval using ln-transformed data. Data on file, Aquestive Therapeutics. 8

Conclusions for COSF Bioequivalence Study (Study 162018) COSF 20 mg is bioequivalent to Onfi 20 mg COSF 10 mg is bioequivalent to Onfi 10 mg T max values for COSF were comparable to those for Onfi COSF is dose proportional over the 10-20 mg range COSF at doses of 10 and 20 mg was safe and well tolerated Data on file, Aquestive Therapeutics. 9

Diazepam Buccal Soluble Film (DBSF) An alternative to Diastat AcuDial (diazepam rectal gel) for the treatment of acute repetitive seizures (seizure clusters)

DBSF Received FDA Fast Track Designation Pre-IND Adult EMU Study NDA Approval Preclinical Formulation Development Pilot Studies Pivotal BA Study Pediatric EMU Study Commercialization Long-term Safety Study Fast track designation with option for rolling submission Expected NDA filings via 505(b)(2) pathway in early 2018 Completed Development Step Ongoing Development Step Future Development Step 11

DBSF: No PK Non-Responders Diastat in some subjects did not produced expected plasma concentrations of diazepam In studies to date, DBSF has exhibited consistent plasma diazepam concentrations including those subjects who did not obtain expected diazepam levels with Diastat Blood Plasma Levels (ng/ml) 600 500 400 300 200 100 0 DBSF Pivotal Pharmacokinetics vs Diastat AcuDial Rectal Gel 1 Individual Subject 0 100 200 300 400 500 600 Time (min) Film - 15mg (subject #7) Gel - 5mg Gel - 12.5mg Gel - 20mg Film - 15mg (all volunteers) DBSF 15 mg Subject #7 All volunteers 1 Fasted conditions 12

Completed Human PK Studies with DBSF Bioavailability of DBSF 5 mg and Diastat AcuDial 5 mg Rectal Gel (Study 1899) Bioavailability of DBSF 20 mg and Diastat AcuDial 20 mg Rectal Gel (Study 1900) Dose Proportionality of DBSF 5, 10, 15 mg (Study 162013) Bioavailability of DBSF 15 mg vs Diastat AcuDial 5, 12.5, and 20 mg Rectal Gel (Study 162921)

Geometric Mean Diazepam Plasma Concentrations (Linear Scale) (Study 162013) Data on file, Aquestive Therapeutics. 14

Dose Proportionality (C max ) (Study 162013) C max by Nominal Dose of Diazepam (Linear Scale) C max values were dose proportional. DBSF: Diazepam 5, 10, 15 mg Buccal Soluble Film. Data on file, Aquestive Therapeutics. 15

Dose Proportionality (AUC 0-t ) (Study 162013) AUC 0-t by Nominal Dose of Diazepam (Linear Scale) AUC 0-t values were dose proportional. DBSF: Diazepam 5, 10, 15 mg Buccal Soluble Film. Data on file, Aquestive Therapeutics. 16

Relative Bioavailability (Study 162021) C max by Nominal Dose of Diazepam (Linear Scale) DBSF C max is known to be dose proportional Diastat AcuDial C max values were less than dose proportional DBSF: Diazepam 15 mg Buccal Soluble Film. Diastat AcuDial: Diazepam 5 mg (1 ml of 10 mg/2 ml), 12.5 mg (2.5 ml of 20 mg/4 ml), and 20 mg (4 ml of 20 mg/4 ml) rectal gel. Data on file, Aquestive Therapeutics. 17

Relative Bioavailability (Study 162021) AUC 0-t by Nominal Dose of Diazepam (Linear Scale) DBSF DBSF is known to be dose proportional for AUC Diastat AcuDial Diastat is dose proportional for AUC DBSF: Diazepam 15 mg Buccal Soluble Film. Diastat AcuDial: Diazepam 5 mg (1 ml of 10 mg/2 ml), 12.5 mg (2.5 ml of 20 mg/4 ml), and 20 mg (4 ml of 20 mg/4 ml) rectal gel. Data on file, Aquestive Therapeutics. 18

Proposed DBSF Dosing: Dose of DBSF in mg Equivalent to Dose of Diastat AcuDial in mg Diastat Dose (mg) Protocol- Specified DBSF Dose 1 (mg) 5 5 7.5 7.5 10 7.5 12.5 10 15 12.5 17.5 12.5 20 12.5 1 Dose of DBSF expected to provide C max equal to C max for Diastat dose. Data on file, Aquestive Therapeutics. 19

PK Features of DBSF vs Diastat AcuDial Dose-proportional kinetics Less intersubject variability No bioavailability failures T max (h)

DBSF Studies Ongoing Adult EMU Study Pediatric EMU Study Long-term Safety Study

The End